Institute of Medicine (IOM). Chapter 2. Profile of rare diseases. IOM (US) committee on accelerating rare diseases research and orphan product development. In: Field MJ, Boat TF (eds). National Academies Press (US), Washington, DC; 2010. https://doi.org/10.17226/12953.
NCOD (National Commission on Orphan Diseases). Report of the national commission on orphan diseases. Public Health Service, U.S. Department of Health and Human Services, Rockville, MD; 1989.
NIH NCATS. Genetics and rare diseases information center. FAQs about rare diseases. https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rare-diseases. Accessed 14 April 2021.
Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, Murphy D, Le Cam Y, Rath A. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28:165–73. https://doi.org/10.1038/s41431-019-0508-0.
Article
PubMed
Google Scholar
Haendel M, Vasilevsky N, Unni D, Bologa C, Harris N, Rehm H, Hamosh A, Baynam G, Groza T, McMurry J, Dawkins J, Rath A, Thaxon C, Bocci G, Joachimiak MP, Kohler S, Robinson PN, Mungall C, Oprea RI. How many rare diseases are there? Nat Rev Drug Discov. 2020;19(2):77–8. https://doi.org/10.1038/d41573-019-00180-y.
Article
CAS
PubMed
PubMed Central
Google Scholar
Online Mendelian Inheritance in Man®: an online catalog of human genes and genetic disorders. OMIM gene map statistics. https://www.omim.org/statistics/geneMap. Accessed 14 April 2021.
Orphanet. Orphanet Report Series. Prevalence and incidence of rare diseases: Bibliographic data. January 2021. https://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_diseases.pdf. Accessed 14 April 2021.
Hartley T, Balci TB, Rojas SK, Eaton A, Care4Rare Canada, Dyment DA, Boycott KM. The unsolved rare genetic disease atlas? An analysis of the unexplained phenotypic descriptions in OMIM®. Am J Med Genet. 2018;178C:458–63. https://doi.org/10.1002/ajmg.c.31662.
Article
CAS
Google Scholar
Klimova B, Storek M, Valis M, Kuca K. Global view on rare diseases: a mini review. Curr Med Chem. 2017;24:3153–8. https://doi.org/10.2174/0929867324666170511111803.
Article
CAS
PubMed
Google Scholar
Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy. 2015;119:964–79. https://doi.org/10.1016/j.healthpol.2014.12.016.
Article
PubMed
Google Scholar
Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, Jain M, Kleijnen J. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12:79. https://doi.org/10.1186/s13023-017-0631-3.
Article
CAS
PubMed
PubMed Central
Google Scholar
EURORDIS. Survey of the delay in diagnosis for 8 rare diseases in Europe (EurordisCare2). Fact Sheet EurordisCare2. 2007. https://www.eurordis.org/publication/survey-delay-diagnosis-8-rare-diseases-europe-%E2%80%98eurordiscare2%E2%80%99. Accessed 14 April 2021.
Molster C, Urwin D, Di Pietro L, Fookes M, Petrie D, van der Laan S, Dawkins H. Survey of healthcare experiences of Australian adults living with rare diseases. Orphanet J Rare Dis. 2016;11:30. https://doi.org/10.1186/s13023-016-0409-z.
Article
PubMed
PubMed Central
Google Scholar
Zhu Q, Nguyen DT, Grishagin I, Southall N, Sid E, Pariser A. An integrative knowledge graph for rare diseases, derived from the Genetic and Rare Diseases Information Center (GARD). J Biomed Semant. 2020;11(1):13. https://doi.org/10.1186/s13326-020-00232-y.
Article
Google Scholar
Boycott KM, Hartley T, Biesecker LG, Gibbs RA, Innes AM, Riess O, Belmont J, Dunwoodie SL, Jojic N, Lassmann T, Mackay D, Temple IK, Visel Z, Baynam G. A diagnosis for all rare genetic diseases: the horizon and the next frontiers. Cell. 2019;1:32–7. https://doi.org/10.1016/j.cell.2019.02.040.
Article
CAS
Google Scholar
Cohen AM, Chamberlin S, Deloughery T, Nguyen M, Bedrick S, Meninger S, Ko JJ, Amin JJ, Wei AJ, Hersh W. Detecting rare diseases in electronic health records using machine learning and knowledge engineering: case study of acute hepatic porphyria. PLoS ONE. 2020;15: e0235574. https://doi.org/10.1371/journal/pone.0235574.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gunne E, McGarvey C, Hamilton K, Treacy E, Lambert DM, Lynch SA. A retrospective review of the contribution of rare diseases to paediatric mortality in Ireland. Orphanet J Rare Dis. 2020;15:311. https://doi.org/10.1186/s13023-020-01574-7.
Article
PubMed
PubMed Central
Google Scholar
Walker CE, Mahede T, Davis G, Miller LJ, Girschik J, Brameld K, Sun W, Rath A, Aymé S, Zubrick SR, Baynam GS, Molster C, Dawkins HJS, Weeramanthri TS. The collective impact of rare diseases in Western Australia: an estimate using a population-based cohort. Genet Med. 2017;19:546–52. https://doi.org/10.1038/gim.2016.143.
Article
PubMed
Google Scholar
Reaven NL, Funk SE, Lyons PD, Story TJ. The direct cost of seizure events in severe childhood-onset epilepsies: a retrospective claims-based analysis. Epilepsy Behav. 2019;93:65–72. https://doi.org/10.1016/j.yebeh.2019.01.045.
Article
PubMed
Google Scholar
Fernandez IS, Amengual-Gual M, Aguilar CB, Loddenkemper T. Estimating the cost of status epilepticus admissions in the United States of America using ICD-10 codes. Seizure. 2019;17:295–303. https://doi.org/10.1016/j.seizure.2019.09.001.
Article
Google Scholar
Everylife Foundation. The national burden of rare disease study. 2021. https://everylifefoundation.org/burden-study/. Accessed 15 April 2021.
Navarrete-Opazo AA, Singh M, Tisdale A, Cutillo CM, Garrison SR. Can you hear us now? The impact of health-care utilization by rare disease patients in the United States. Genet Med. 2021. https://doi.org/10.1038/s41436-021-01241-7.
Article
PubMed
Google Scholar
Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, Baldoli C, Martino S, Calabria A, Canale S, Benedicenti F, Vallanti G, Biasco L, Leo S, Kabbara N, Zanetti G, Rizzo WB, Mehta NAL, Cicalese MP, Casiraghi M, Boelens JJ, Del Carro U, Dow DJ, Schmidt M, Assanelli A, Neduva V, Di Serio C, Stupka E, Gardner J, von Kalle C, Bordignon C, Ciceri F, Rovelli A, Roncarolo MG, Aiuti A, Sessa M, Naldini L. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013;341:1233158. https://doi.org/10.1126/science.1233158.
Article
CAS
PubMed
Google Scholar
Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC, for the ENDEAR Study Group. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723–32. https://doi.org/10.1056/NEJMoa1702752.
Article
CAS
PubMed
Google Scholar
Australian Government. Australian Institute of Health and Welfare (AIHW). Australian refined diagnosis-related groups (AR-DRG) data cubes. Updated 07-Dec-2020. https://www.aihw.gov.au/reports/hospitals/ar-drg-data-cubes/contents/data-cubes. Accessed 27 April 2021.
Dimitropoulos V, Yeend T, Zhou Q, McAlister S, Navakatikyan M, Hoyle P, Pilla J, Loggie C, Elsworthy A, Marshall R, Madden R. A new clinical complexity model for the Australian refined diagnosis related groups. Health Policy. 2019;123:1049–52. https://doi.org/10.1016/j.healthpol.2019.08.012.
Article
PubMed
Google Scholar
Garcia M, Downs J, Russel A, Wang W. Impact of biobanks on research outcomes in rare diseases: a systematic review. Orphanet J Rare Dis. 2018;13:202. https://doi.org/10.1186/s13023-018-0942-z.
Article
PubMed
PubMed Central
Google Scholar
Rubinstein YR, Robinson PN, Gahl WA, Avillach P, Baynam G, Cederroth H, Goodwin RM, Groft SC, Hansson MG, Harris NL, Huser V, Mascalzoni D, McMurry JA, Might M, Nellaker C, Mons B, Paltoo DN, Pevsner J, Posada M, Rockett-Frase AP, Roos M, Rubinstein TB, Taruscio D, van Enckevort E, Haendel MA. The case for open science: rare diseases. JAMIA Open. 2020;3:4720486. https://doi.org/10.1093/jamiaopen/ooaa030.
Article
Google Scholar
Feng LB, Grosse SD, Green RF, Fink AK, Sawicki GS. Precision medicine in action: the impact of ivacaftor on cystic fibrosis-related hospitalizations. Health Aff. 2017;37:773–9. https://doi.org/10.1377/hlthaff.2017.1554.
Article
Google Scholar
PR Newswire. Finn Partners national survey reveals how fragmented health system places greater burden on patients. https://www.prnewswire.com/news-releases/finn-partners-national-survey-reveals-how-fragmented-health-system-places-greater-burden-on-patients-300217167.html. Accessed 27 April 2021.
Park J, Look KA. Health care expenditure burden of cancer care in the United States. Inquiry. 2019;56:1–9. https://doi.org/10.1177/0046958019880696.
Article
Google Scholar
Urbich M, Globe G, Pantiri K, Heisen M, Bennison C, Wirtz HS, Di Tanna GL. A systematic review of medical costs associated with heart failure in the USA (2014–2020). Pharmacoeconomics. 2020;38:1219–36. https://doi.org/10.1007/s40273-020-00952-0.
Article
PubMed
PubMed Central
Google Scholar
Wong W. Economic burden of Alzheimer disease and managed care considerations. Am J Manag Care. 2020;26:S177–83. https://doi.org/10.37765/ajmc.2020.88482.
Article
PubMed
Google Scholar
Costain G, Walker S, Marano M, Veenma D, Snell M, Curtis M, Luca S, Buera J, Arje D, Reuter MS, Thiruvahindrapuram B, Trost B, Sung WWL, Yuen RK, Chirayat D, Mendoza-Londono R, Stavropoulos J, Scherer SW, Marshall CR, Cohn RD, Cohen E, Orkin J, Meyn MS, Hayeems RZ. Genome sequencing as a diagnostic test in children with unexplained medical complexity. JAMA Netw Open. 2020;3:e2018109. https://doi.org/10.1001/jamanetworkopen.2020.18109.
Article
PubMed
PubMed Central
Google Scholar
Farnaes L, Hildreth A, Sweeney NM, Clark MM, Chowdhury S, Nahas S, Cakici JA, Benson W, Kaplan RH, Kronick R, Bainbridge MN, Friedman J, Gold JJ, Ding Y, Veeraraghavan N, Dimmock D, Kingsmore SF. Rapid whole-genome sequencing decreases infant morbidity and cost of hospitalization. NPJ Genom Med. 2018;3:10. https://doi.org/10.1038/s41525-018-0049-4.
Article
CAS
PubMed
PubMed Central
Google Scholar
Grosse SD, Farnaes L. Genomic sequencing in acutely ill infants: what will it take to demonstrate clinical value? Genet Med. 2018. https://doi.org/10.1038/s41436-018-0124-3.
Article
PubMed
PubMed Central
Google Scholar
Reuter CM, Kohler JN, Bonner D, Zastrow D, Fernandez L, Dries A, Marwaha S, Davidson J, Brokamp E, Herzog M, Hong J, Macnamara E, Rosenfeld JA, Schoch K, Spillmann R, Undiagnosed Diseases Network, Loscalzo J, Krier J, Stoler J, Sweetser D, Palmer CGS, Phillips JA, Shashi V, Adams DA, Yang Y, Ashley EA, Fisher PG, Mulvihill JJ, Bernstein JA, Wheeler MT. Yield of whole exome sequencing in undiagnosed patients facing insurance coverage barriers to genetic testing. J Genet Couns. 2019;28:1107–18. https://doi.org/10.1002/jgc4.1161.
Article
PubMed
PubMed Central
Google Scholar
National Organization for Rare Disorders. Rare Disease Database. 2021. https://rarediseases.org/for-patients-and-families/information-resources/rare-disease-information/. Accessed 15 April 2021.
Summar ML, Koelker S, Freedenberg D, Le Mons C, Haberle J, Lee HS, Kirmse B. The European Registry and network for intoxication type metabolic diseases (E-IMD), and the members of the urea cycle disorders consortium (UCDC). The incidence of urea cycle disorders. Mol Genet Metab. 2013;110(1–2):179–80. https://doi.org/10.1016/j.ymgme.2013.07.008.
Article
CAS
PubMed
PubMed Central
Google Scholar
ASCO®. Cancer.net. Pheochromocytoma and Paraganglioma: Statistics. 2021. https://www.cancer.net/cancer-types/pheochromocytoma-and-paraganglioma/statistics#:~:text=Pheochromocytomas%20and%20paragangliomas%20are%20rare,of%20these%20cases%20are%20malignant. Accessed 15 April 2021.
Orphanet. The portal for rare diseases and orphan drugs. Mitochondrial neurogastrointestinal encephalomyopathy. 2021. https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=298. Accessed 15 April 2021.